君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01877 君实生物

休市中 11-06 16:08:52

15.690

-0.240

-1.51%

最高16.010	最低15.240	成交量146.94万
今开15.490	昨收15.930	日振幅4.83%
总市值161.14亿	流通市值40.79亿	总股本10.27亿
成交额2,301万	换手率0.57%	流通股本2.60亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":15.69,"timestamp":1793952532005,"preClose":15.93,"halted":0,"volume":1469400,"delay":0,"changeRate":-0.01506591337099813,"floatShares":260000000,"shares":1027000000,"eps":-0.87,"marketStatus":"休市中","change":-0.24,"latestTime":"11-06 16:08:52","open":15.49,"high":16.01,"low":15.24,"amount":23005563,"amplitude":0.048336,"askPrice":15.69,"askSize":2000,"bidPrice":15.65,"bidSize":1200,"shortable":3,"etf":0,"ttmEps":-0.448,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":7,"adr":0,"listingDate":1545580800000,"exchange":"SEHK","adjPreClose":15.93,"openAndCloseTimeList":[[1793928600000,1793937600000],[1793941200000,1793952000000]],"volumeRatio":0.8721994526916772,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物-U","latestPrice":30.85,"timestamp":1793948400000,"preClose":31.29,"halted":0,"volume":9210000,"delay":0,"premium":"-56.74"}},"requestUrl":"/m/hq/s/01877","defaultTab":"news","newsList":[{"id":"2681884019","title":"【券商聚焦】中信建投评26 ESMO：中国创新药持续突破，竞争与差异化并存","url":"https://stock-news.laohu8.com/highlight/detail?id=2681884019","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681884019?lang=zh_cn&edition=full","pubTime":"2026-11-06 08:57","pubTimestamp":1793926628,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年欧洲内科肿瘤学会（European Society for Medical Oncology，ESMO）中，中国创新药在多瘤种领域全面发力，众多项目从早期探索迈入III期临床或BLA/NDA阶段。国内药企已在IO双抗及多抗、ADC、小分子靶向等赛道形成多线并进格局，III期阳性终点多点开花，持续产出具备国际竞争力的临床数据，标志着中国创新药研发不断从跟随创新迈向源头创新与全球引领的新阶段，行业发展逻辑从“fast-follow”迈入“first-in-class”与“best-in-class”并行的阶段。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995351","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128522744.USD","01093","09995","09926","LU1242518857.USD","LU0039217434.USD","IE00BPRC5H50.USD","LU2488822045.USD","LU2097828714.EUR","01877","LU0516422952.EUR","LU0228659784.USD","LU0708995153.HKD","LU1226287529.USD","LU1251922891.USD","LU2097828474.EUR","LU0594300179.USD","KURE","LU0823426308.USD","LU1960683339.HKD","LU2242644610.SGD","BK1191","09688","BK1574","LU0634319403.HKD","BK1515","LU1813983027.USD","LU1152091754.HKD","LU1152091168.USD","LU0417516571.SGD","06185","601066","02142","LU0348766576.USD","LU0348783233.USD","LU1807302812.USD","02269","LU0320764243.SGD","LU1242518931.SGD","LU1188198961.HKD","02616","LU0456827905.SGD","06160","LU0315179316.USD","KCE","LU0540923850.HKD","01801","01177","LU0455707207.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681003873","title":"股市必读：君实生物新发布《君实生物H股公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2681003873","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681003873?lang=zh_cn&edition=full","pubTime":"2026-11-06 01:11","pubTimestamp":1793898676,"startTime":"0","endTime":"0","summary":"公司公告汇总君实生物H股公告上海君实生物医药科技股份有限公司截至2026年10月31日的证券变动月报表显示，公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。H股于香港联交所上市，A股于上交所科创板上市。股份期权计划方面，H股及A股股票期权激励计划于2025年9月29日获批准采纳，本月内未发生行使期权导致的新股发行或库存股份转让。确认已符合香港上市规则规定的公众持股量要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600001687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","01877","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680057180","title":"君实生物（688180）披露截至2026年10月31日证券变动月报表，11月04日股价上涨5.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680057180","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680057180?lang=zh_cn&edition=full","pubTime":"2026-11-04 22:13","pubTimestamp":1793801598,"startTime":"0","endTime":"0","summary":"截至2026年11月4日收盘，君实生物报收于31.02元，较前一交易日上涨5.87%，最新总市值为318.48亿元。近日，君实生物发布H股公告，披露截至2026年10月31日的证券变动月报表。公告显示，公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。H股于香港联交所上市，A股于上交所科创板上市。股份期权计划方面，H股及A股股票期权激励计划于2025年9月29日获批准采纳，本月内未发生行使期权导致的新股发行或库存股份转让。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400043559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","BK0239","01877","161027","BK1161","BK1515","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680075587","title":"中金：维持君实生物(01877.HK)“跑赢行业”评级 目标价21.3港元 创新研发管线逐步进入收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2680075587","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680075587?lang=zh_cn&edition=full","pubTime":"2026-11-04 09:29","pubTimestamp":1793755754,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","01877","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680200610","title":"股市必读：君实生物三季报 - 第三季度单季净利润同比增长6.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680200610","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680200610?lang=zh_cn&edition=full","pubTime":"2026-11-02 04:39","pubTimestamp":1793565548,"startTime":"0","endTime":"0","summary":"股本股东变化：截至2026年9月30日股东户数为3.89万户，较6月30日增加3.28%。业绩披露要点：2026年前三季度归母净利润为-1.49亿元，同比上升74.95%，亏损显著缩窄。第三季度单季度主营收入8.17亿元，同比上升28.19%；单季度归母净利润-1.71亿元，同比上升6.63%；单季度扣非净利润-3565.3万元，同比上升81.37%；负债率59.58%，投资收益9715.23万元，财务费用1.08亿元，毛利率82.73%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200001373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679218044","title":"君实生物(688180)9月30日股东户数3.89万户，较上期增加3.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679218044","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679218044?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:11","pubTimestamp":1793358674,"startTime":"0","endTime":"0","summary":"证券之星消息，近日君实生物披露，截至2026年9月30日公司股东户数为3.89万户，较6月30日增加1238.0户，增幅为3.28%。户均持股数量由上期的2.03万股减少至1.97万股，户均持股市值为70.17万元。在生物制品行业个股中，君实生物股东户数高于行业平均水平，截至9月30日，生物制品行业平均股东户数为3.67万户。从股价来看，2026年6月30日至2026年9月30日，君实生物区间涨幅为5.44%，在此期间股东户数增加1238.0户，增幅为3.28%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000046498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","688180","BK1515","BK0239","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679943502","title":"破发股君实生物连亏10年3季 上市2募资共86亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679943502","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679943502?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:51","pubTimestamp":1793353873,"startTime":"0","endTime":"0","summary":"中国经济网北京10月30日讯 君实生物 昨日披露2026年三季度报告。前三季度，公司实现营业收入25.13亿元，同比增长39.18%；归属于上市公司股东的净利润为-1.49亿元；归属于上市公司股东的扣非净利润为-2.39亿元；经营活动产生的现金流量净额为1.66亿元。　　君实生物首次公开发行股票募集资金总额为48.36亿元，扣除发行费用后，募集资金净额为44.97亿元，较原计划多17.97亿元。　　君实生物首次公开发行股票发行费用为3.39亿元，其中，保荐及承销费用3.20亿元。","market":"fut","thumbnail":" //caiji3g.cnfol.com/colect/202610/30/20261030757770.png","type":0,"news_type":0,"thumbnails":[" //caiji3g.cnfol.com/colect/202610/30/20261030757770.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20261030/32412185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","BK1515","01877","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679649862","title":"港股异动 | 君实生物(01877.HK)跌超3% 前三季度归母净亏损同比收窄75% JS207-017-III-HCC研究完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2679649862","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679649862?lang=zh_cn&edition=full","pubTime":"2026-10-30 15:09","pubTimestamp":1793344173,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","01877","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679762231","title":"图解君实生物三季报：第三季度单季净利润同比增长6.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679762231","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679762231?lang=zh_cn&edition=full","pubTime":"2026-10-30 04:44","pubTimestamp":1793306649,"startTime":"0","endTime":"0","summary":"证券之星消息，君实生物2026年三季报显示，前三季度公司主营收入25.13亿元，同比上升39.18%；归母净利润-1.49亿元，同比上升74.95%；扣非净利润-2.39亿元，同比上升64.3%；其中2026年第三季度，公司单季度主营收入8.17亿元，同比上升28.19%；单季度归母净利润-1.71亿元，同比上升6.63%；单季度扣非净利润-3565.3万元，同比上升81.37%；负债率59.58%，投资收益9715.23万元，财务费用1.08亿元，毛利率82.73%。财报数据概要请见下图:本文数据来源于君实生物2026年三季报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000006236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141998194","title":"君实生物(01877)拟最高20亿元暂闲募资开展一年期现金管理","url":"https://stock-news.laohu8.com/highlight/detail?id=1141998194","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141998194?lang=zh_cn&edition=full","pubTime":"2026-10-29 21:45","pubTimestamp":1793281531,"startTime":"0","endTime":"0","summary":"2026年10月30日，上海君实生物医药科技股份有限公司公告称，公司第四届董事会第二十四次会议于2026年10月29日审议通过《关于使用暂时闲置募集资金进行现金管理的议案》，同意自2026年11月27日至2027年11月26日期间，使用最高不超过20亿元的暂时闲置募集资金投资于安全性高、流动性好的保本型产品，包括但不限于通知存款、定期存款、协定存款、组合存款、存单及结构性存款等。资金可在额度及期限内循环滚动使用。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163752388","title":"君实生物（01877）前三季度营收同比增39.18%至25.13亿元 经营现金流转正","url":"https://stock-news.laohu8.com/highlight/detail?id=1163752388","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163752388?lang=zh_cn&edition=full","pubTime":"2026-10-29 21:35","pubTimestamp":1793280930,"startTime":"0","endTime":"0","summary":"2026年10月29日，君实生物医药科技股份有限公司披露2026年第三季度报告。公告显示，公司前三季度实现营业收入25.13亿元，同比增长39.18%；其中第三季度单季实现营业收入8.17亿元，同比增长28.19%。报告期内，公司实现利润总额-2.48亿元，同比亏损收窄；归属于上市公司股东的净利润为-1.49亿元，上年同期为-5.96亿元。研发投入方面，前三季度公司投入9.84亿元，占营业收入的39.15%，同比减少15.24个百分点。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679283692","title":"君实生物(01877)前三季度归母净亏损1.49亿元，同比收窄75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679283692","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679283692?lang=zh_cn&edition=full","pubTime":"2026-10-29 21:35","pubTimestamp":1793280907,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物(01877)发布公告，2026年前三季度，营业收入25.13亿元，同比增长39.18%;归属于上市公司股东的净亏损1.49亿元，同比收窄75%;基本每股亏损0.15元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01877","BK1583","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176721254","title":"君实生物（01877）将于11月5日举行2026年第三季度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=1176721254","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176721254?lang=zh_cn&edition=full","pubTime":"2026-10-29 20:50","pubTimestamp":1793278230,"startTime":"0","endTime":"0","summary":"君实生物10月30日在上海证券交易所网站披露，公司拟于2026年11月5日13:00-14:00通过上证路演中心举行2026年第三季度业绩说明会。本次说明会采用网络互动形式，旨在就投资者关注的经营成果及财务指标进行沟通。公司方面，执行董事、总经理兼首席执行官邹建军女士，独立非执行董事郦仲贤先生，财务总监许宝红先生及董事会秘书王征宇先生将出席说明会。会后，投资者可通过上证路演中心查看说明会的召开情况及主要内容。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109527480","title":"君实生物（01877）III期肝癌新药JS207联合JS007完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1109527480","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109527480?lang=zh_cn&edition=full","pubTime":"2026-10-29 20:16","pubTimestamp":1793276163,"startTime":"0","endTime":"0","summary":"2026年10月30日，君实生物发布公告称，公司自主研发的重组人源化抗PD-1和VEGF双特异性抗体JS207联合抗CTLA-4单克隆抗体JS007，用于一线治疗晚期肝细胞癌的多中心、随机、对照、开放III期临床研究已完成首例患者给药。该研究计划入组560例受试者，主要终点为无进展生存期和总生存期。君实生物表示，将按照相关规定及时披露项目进展信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679404299","title":"君实生物(01877)：JS207联合JS007用于一线治疗晚期肝细胞癌的III期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2679404299","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679404299?lang=zh_cn&edition=full","pubTime":"2026-10-29 20:15","pubTimestamp":1793276140,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物 发布公告，近日，公司产品重组人源化抗 PD-1 和 VEGF 双特异性抗体联合重组人源化抗 CTLA4 单克隆抗体对比特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的有效性和安全性的多中心、随机、对照、开放 III 期临床研究已完成首例患者给药。本研究为 JS207 的首个国内注册临床研究。JS007 是公司自主研发的重组人源化抗 CTLA-4 单克隆抗体注射液，主要用于晚期恶性肿瘤的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","IBBJ","BMED","BK1583","BK1161","MDTX","01877","IBBQ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154520129","title":"君实生物（01877）宣布JS207联合JS007一线治疗晚期肝细胞癌III期临床试验完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1154520129","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154520129?lang=zh_cn&edition=full","pubTime":"2026-10-29 20:15","pubTimestamp":1793276132,"startTime":"0","endTime":"0","summary":"上海君实生物医药科技股份有限公司（01877）10月29日发布自愿性公告称，公司自主研发的重组人源化抗PD-1和VEGF双特异性抗体JS207联合重组人源化抗CTLA-4单克隆抗体JS007，用于一线治疗晚期肝细胞癌（HCC）的多中心、随机、对照、开放的III期临床研究（JS207-017-III-HCC，注册号：NCT07823348）已于近日完成首例患者给药。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192130996","title":"君实生物（01877.HK）拟以不超20亿元闲置募资进行一年期现金管理","url":"https://stock-news.laohu8.com/highlight/detail?id=1192130996","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192130996?lang=zh_cn&edition=full","pubTime":"2026-10-29 20:05","pubTimestamp":1793275544,"startTime":"0","endTime":"0","summary":"上海君实生物医药科技股份有限公司（01877.HK）10月29日公告称，公司董事会已审议通过《关于使用暂时闲置募集资金进行现金管理的议案》，拟自2026年11月27日至2027年11月26日期间，使用额度不超过人民币20亿元（含本数）的暂时闲置募集资金购买安全性高、流动性好的保本型银行理财及存款类产品，资金可在额度和期限内滚动使用。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135584170","title":"君实生物JS001sc一线治疗HER2表达尿路上皮癌新适应症获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1135584170","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135584170?lang=zh_cn&edition=full","pubTime":"2026-10-28 22:01","pubTimestamp":1793196090,"startTime":"0","endTime":"0","summary":"2026年10月28日，上海君实生物医药科技股份有限公司发布自愿性公告称，公司已收到国家药品监督管理局核准签发的《受理通知书》，受理号CXSS2600173，受理其特瑞普利单抗注射液联合维迪西妥单抗用于HER2表达的局部晚期或转移性尿路上皮癌一线治疗的新适应症上市申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138860740","title":"君实生物（01877.HK）特瑞普利单抗获国家药监局常规批准用于含铂化疗失败的晚期尿路上皮癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1138860740","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138860740?lang=zh_cn&edition=full","pubTime":"2026-10-28 21:55","pubTimestamp":1793195759,"startTime":"0","endTime":"0","summary":"2026年10月28日，君实生物发布自愿性公告称，公司已收到国家药品监督管理局签发的《药品补充申请批准通知书》，批准其自主研发的特瑞普利单抗注射液“单药适用于含铂化疗失败包括新辅助或辅助化疗12个月内进展的局部晚期或转移性尿路上皮癌”适应症，由附条件批准转为常规批准。此次批准对应的受理号为CYSB2600232、CYSB2600233，通知书编号为2026B07469、2026B07470，上市许可持有人均为上海君实生物医药科技股份有限公司。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197420295","title":"君实生物（01877）特瑞普利单抗获国家药监局常规批准用于含铂化疗失败的晚期尿路上皮癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1197420295","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197420295?lang=zh_cn&edition=full","pubTime":"2026-10-28 20:21","pubTimestamp":1793190067,"startTime":"0","endTime":"0","summary":"2026年10月29日，君实生物公告称，公司已收到国家药品监督管理局签发的《药品补充申请批准通知书》，批准其PD-1单抗产品特瑞普利单抗注射液“单药适用于含铂化疗失败包括新辅助或辅助化疗12个月内进展的局部晚期或转移性尿路上皮癌”的适应症，由附条件批准转为常规批准。此次获批的受理号为CYSB2600232、CYSB2600233，通知书编号为2026B07469、2026B07470。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://junshipharma.com","stockEarnings":[{"period":"1week","weight":0.0282},{"period":"1month","weight":-0.123},{"period":"3month","weight":-0.1946},{"period":"6month","weight":-0.3591},{"period":"1year","weight":-0.3961},{"period":"ytd","weight":-0.2648}],"compareEarnings":[{"period":"1week","weight":0.051},{"period":"1month","weight":0.0146},{"period":"3month","weight":-0.0462},{"period":"6month","weight":-0.0724},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":-0.0448}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海君实生物医药科技股份有限公司是一家主要从事创新驱动生物制药业务的中国公司。该公司主营业务为创新药物的发现、临床研究和开发。该公司的主要产品包括特立普珠单抗注射液、依替维单抗、阿达木单抗注射液等用于治疗恶性肿瘤、自身免疫系统疾病、慢性代谢疾病、神经系统疾病和感染性疾病的药物。该公司还从事重组人源化抗PCSK9单克隆抗体注射液等药物的临床研发。该公司主要为国内外市场提供产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.098181},{"month":2,"riseRate":0.75,"avgChangeRate":0.062525},{"month":3,"riseRate":0.75,"avgChangeRate":0.059343},{"month":4,"riseRate":0.875,"avgChangeRate":0.105939},{"month":5,"riseRate":0.375,"avgChangeRate":-0.021039},{"month":6,"riseRate":0.375,"avgChangeRate":-0.04216},{"month":7,"riseRate":0.625,"avgChangeRate":-0.000677},{"month":8,"riseRate":0.125,"avgChangeRate":-0.039004},{"month":9,"riseRate":0.25,"avgChangeRate":-0.011976},{"month":10,"riseRate":0.25,"avgChangeRate":-0.030119},{"month":11,"riseRate":0.625,"avgChangeRate":0.041806},{"month":12,"riseRate":0.571429,"avgChangeRate":0.085319}],"exchange":"SEHK","name":"君实生物","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,01877,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}